328 related articles for article (PubMed ID: 6210188)
1. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
Klapdor R; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
[No Abstract] [Full Text] [Related]
2. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
Safi F; Büchler M; Schenkluhn B; Beger HG
Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
[TBL] [Abstract][Full Text] [Related]
3. [Ganglioside and carcinoembryonic antigens in the diagnosis of malignant tumors of the gastrointestinal tract].
Ivanov PK; Samoĭlenko VM
Vopr Onkol; 1984; 30(9):55-9. PubMed ID: 6495695
[TBL] [Abstract][Full Text] [Related]
4. [CA-19-9, CA50 and CEA in pancreatic and gastrointestinal tumors. Comparative studies].
Dienst C; Clodius T; Oldörp T; Uhlenbruck G; Diehl V
Med Klin (Munich); 1987 Jan; 82(2):45-50. PubMed ID: 3470595
[No Abstract] [Full Text] [Related]
5. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
6. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of CA 50 and CA 19-9 tumor markers in benign and malignant diseases of the upper gastrointestinal tract].
Heptner G; Domschke S; Schneider MU; Siegfried W; Domschke W
Dtsch Med Wochenschr; 1986 Mar; 111(10):374-8. PubMed ID: 2419074
[TBL] [Abstract][Full Text] [Related]
8. [New monoclonal antibodies in the diagnosis of gastrointestinal cancers].
Heptner G; Domschke S; Domschke W
Internist (Berl); 1986 Nov; 27(11):723-8. PubMed ID: 2433247
[No Abstract] [Full Text] [Related]
9. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of CA 19-9 (carbohydrate antigen) in gastrointestinal adenocarcinoma.
Mennini G; Silecchia G; Zanna C; Cucchiara G; Spadaro G; Greco E; Basoli A; Speranza V
Ital J Surg Sci; 1985; 15(1):37-43. PubMed ID: 3858272
[TBL] [Abstract][Full Text] [Related]
12. [Biohumeral markers in the diagnosis of pancreatic carcinoma].
Panucci A; Del Favero G; Falmis C; Brosolo P; Basso D; Pedrazzoli S; Baccaglini U; Marchioro L; Bonvilini P; Naccarato R
Recenti Prog Med; 1985; 76(7-8):385-91. PubMed ID: 3865269
[No Abstract] [Full Text] [Related]
13. Immunologic diagnosis and prognosis of human digestive-tract cancer: carcinoembryonic antigens.
Zamcheck N; Moore TL; Dhar P; Kupchik H
N Engl J Med; 1972 Jan; 286(2):83-6. PubMed ID: 4107622
[No Abstract] [Full Text] [Related]
14. [CA-50: evaluation of a new tumor marker in the diagnosis of neoplastic pathologies of the gastrointestinal tract].
Pecchio F; Ricci E; Rapellino M; Oliaro A; Adamo MR; Marzola G; Piantino P
Minerva Med; 1987 Feb; 78(3):141-4. PubMed ID: 3469541
[TBL] [Abstract][Full Text] [Related]
15. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
Staab HJ
Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
[No Abstract] [Full Text] [Related]
16. [Diagnosis of recurrence and evaluation of the course of pancreatic cancer. Combined use of sonography and the new tumor marker CA 19-9].
Guthoff A; Klapdor U; Klapdor R; Eichfuss HP; Dallek M; Greten H
Dtsch Med Wochenschr; 1984 Sep; 109(37):1410-2. PubMed ID: 6383759
[No Abstract] [Full Text] [Related]
17. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis of tumors with the use of immunologic tumor markers].
Vorlaender KO
Wien Med Wochenschr; 1983 Feb; 133(3):59-66. PubMed ID: 6189301
[No Abstract] [Full Text] [Related]
19. [Introduction of a new laboratory marker for cancer of the pancreas (CA 19.9). Current experience].
Nunes AP; Jukemura J; Machado MC; Scheinberg MA
Rev Paul Med; 1986; 104(2):99-101. PubMed ID: 3468583
[No Abstract] [Full Text] [Related]
20. Immunologic diagnosis of human digestive tract cancer. Carcinoembryonic antigens.
Kamholz SL
Am J Gastroenterol; 1973 Mar; 59(3):233-43. PubMed ID: 4121819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
